Pharmacy and Biomedical Sciences

Profile

Qualifications

BSc, PhD

Internal Advisory Boards and Committees

• Chair, University of Portsmouth Athena Swan Group
• Head, Pharmacology and Clinical Immunology Division
• School of Pharmacy and Biomedical Sciences Research and Knowledge Transfer Committee member
• University of Portsmouth Peer Review College member

External Advisory Boards and Committees

• Member - Scientific Research Advisory Committee for the Cystic Fibrosis Trust, 2004 - to date
• Member - Board of Reviewers for the Canadian Cystic Fibrosis Foundation, 2008 - to date
• Editorial Board for Inflammation Research
• Board of Reviewers for Biomarkers

Membership of Societies

• Member of the British Association for Lung research
• Member of the European Cystic Fibrosis Society
• Member of the European Respiratory Society
• Member of the British Pharmacological Society

Key teaching responsibilities

• Level 2; Basic immunology, inflammatory diseases and respiratory physiology
• MSc; The pathogenesis and treatment of cystic fibrosis and chronic obstructive pulmonary disease
• Level 3; Pharmacology project supervision
• M Level; Pharmacy project supervision
• Postgraduate level; Director of Studies for three PhD students and three MD students

Key research interests

• Mechanisms of lung inflammation, tissue damage and repair in cystic fibrosis
• Development of novel mucolytics and new therapeutic applications for heparin
• Mechanisms of epithelial repair in asthma
• Mechanisms of inflammatory cell recruitment and its pharmacological manipulation
• Key research grants obtained in the last 5 years include the Dunhill Medical Trust, the Cystic Fibrosis Trust,  the BBSRC/MoD and Asthma UK

Recent Publications

More recent publications

Publications before 2006

1. Serisier D, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP. Inhaled heparin in cystic fibrosis. Eur Respir J 2006; 27:354-358.
2. Palmer KT, McNeill-Love R, Poole JR, Coggon D, Frew AJ, Linaker CH, Shute JK. Inflammatory responses to the occupational inhalation of metal fume. Eur Respir J 2006; 27: 366-373.
3. Broughton-Head VJ, Smith JR, Shur J, Shute JK. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharm Ther. 2007; 20: 708-717
4. Hilliard TN, Regamey N, Shute JK, Nicholson A, Alton EW, Bush A, Davies JC. Airway remodelling in children with cystic fibrosis, Thorax 2007; 62: 1074-1080. Epub May 2007
5. Broughton-Head VJ, Shur J, Carroll MP, Smith JR, Shute JK. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1240-1249 Epub Sep 2007
6. Perrio MJ, Ewen D, Trevethick MA, Salmon GP, Shute JK. Fibrin formation by wounded bronchial epithelial cell layers in vitro is essential for normal epithelial repair and independent of plasma proteins. Clin Exp Allergy 2007; 37: 1688-1700. Epub Sep 2007.